Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Patrice P. Cacoub; Maria Teresa B Abola; Iris Baumgartner; Deepak L. Bhatt; Mark A. Creager; Chiau Suong Liau; Shinya Goto; Joachim Röther; P. Gabriel Steg; Alan T. Hirsch

doi:10.1016/j.atherosclerosis.2008.10.023

Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Patrice P. Cacoub, Maria Teresa B Abola, Iris Baumgartner, Deepak L. Bhatt, Mark A. Creager, Chiau Suong Liau, Shinya Goto, Joachim Röther, P. Gabriel Steg, Alan T. Hirsch

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

216 Scopus citations

Abstract

Objectives: To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates. Methods: The REACH Registry recruited >68000 outpatients aged ≥45 years with established atherothrombotic disease or ≥3 RFs for atherothrombosis. The predictors of RF control that were evaluated included: (1) patient demographics, (2) mode of PAD diagnosis, and (3) concomitant CAD and/or CVD. Results: RF control was less frequent in patients with PAD (n = 8322), compared with those with CAD or CVD (but no PAD, n = 47492) [blood pressure; glycemia; total cholesterol; smoking cessation (each P < 0.001)]. Factors independently associated with optimal RF control in patients with PAD were male gender (OR = 1.9); residence in North America (OR = 3.5), Japan (OR = 2.5) or Latin America (OR = 1.5); previous coronary revascularization (OR = 1.3); and statin use (OR = 1.4); whereas prior leg amputation was a negative predictor (OR = 0.7) (P < 0.001). Optimal RF control was associated with fewer 1-year CV ischemic symptoms or events. Conclusions: Patients with PAD do not achieve RF control as frequently as individuals with CAD or CVD. Improved RF control is associated with a positive impact on 1-year CV event rates.

Original language	English (US)
Pages (from-to)	e86-e92
Journal	Atherosclerosis
Volume	204
Issue number	2
DOIs	https://doi.org/10.1016/j.atherosclerosis.2008.10.023
State	Published - Jun 2009

Bibliographical note

Funding Information:
Funding: The REACH Registry is sponsored by sanofi-aventis (Paris, France), Bristol-Myers Squibb (Princetown, New Jersey, USA), and the Waksman Foundation (Tokyo, Japan). The sponsors provide logistical support. All the publication activity is controlled by the REACH Registry Global Publication Committee (Ph. Gabriel Steg, Deepak L. Bhatt, Mark Alberts, Ralph D’Agostino, Kim Eagle, Shinya Goto, Alan T. Hirsch, Chiau-Suong Liau, Jean-Louis Mas, E. Magnus Ohman, Joachim Röther, Sidney C. Smith, Peter W.F. Wilson). All manuscripts in the REACH Registry are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publication committee before submission. The funding sponsors have the opportunity to review manuscript submissions but do not have authority to change any aspect of a manuscript.

Funding Information:
Prof. Creager is the recipient of research grants from sanofi-aventis and Merck and is on the speaker's bureau for the Bristol-Myers Squibb – sanofi-aventis Partnership. He is a consultant for Genzyme, Merck, Sigma Tau, and Vascutec.

Funding Information:
Dr. Hirsch has received research grants from Bristol-Myers Squibb and sanofi-aventis and honoraria from sanofi-aventis.

Funding Information:
Prof. Steg has received honoraria for advisory board attendance and consulting fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharpe and Dohme, Nycomed, sanofi-aventis, Servier, Takeda, The Medicines Company; speakers bureau from Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Nycomed, sanofi-aventis, Servier, ZLB Behring and Research Grant from sanofi-aventis within the last 3 years.

Keywords

Cardiovascular events
Cohort study
Peripheral artery disease
REACH Registry
Risk factor control

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.atherosclerosis.2008.10.023

Find It

Find It at U of M Libraries

Cite this

Cacoub, P. P., Abola, M. T. B., Baumgartner, I., Bhatt, D. L., Creager, M. A., Liau, C. S., Goto, S., Röther, J., Steg, P. G., & Hirsch, A. T. (2009). Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis, 204(2), e86-e92. https://doi.org/10.1016/j.atherosclerosis.2008.10.023

Cacoub, PP, Abola, MTB, Baumgartner, I, Bhatt, DL, Creager, MA, Liau, CS, Goto, S, Röther, J, Steg, PG & Hirsch, AT 2009, 'Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry', Atherosclerosis, vol. 204, no. 2, pp. e86-e92. https://doi.org/10.1016/j.atherosclerosis.2008.10.023

@article{980b5af478d04edcaae532ae16c63c65,

title = "Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry",

abstract = "Objectives: To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates. Methods: The REACH Registry recruited >68000 outpatients aged ≥45 years with established atherothrombotic disease or ≥3 RFs for atherothrombosis. The predictors of RF control that were evaluated included: (1) patient demographics, (2) mode of PAD diagnosis, and (3) concomitant CAD and/or CVD. Results: RF control was less frequent in patients with PAD (n = 8322), compared with those with CAD or CVD (but no PAD, n = 47492) [blood pressure; glycemia; total cholesterol; smoking cessation (each P < 0.001)]. Factors independently associated with optimal RF control in patients with PAD were male gender (OR = 1.9); residence in North America (OR = 3.5), Japan (OR = 2.5) or Latin America (OR = 1.5); previous coronary revascularization (OR = 1.3); and statin use (OR = 1.4); whereas prior leg amputation was a negative predictor (OR = 0.7) (P < 0.001). Optimal RF control was associated with fewer 1-year CV ischemic symptoms or events. Conclusions: Patients with PAD do not achieve RF control as frequently as individuals with CAD or CVD. Improved RF control is associated with a positive impact on 1-year CV event rates.",

keywords = "Cardiovascular events, Cohort study, Peripheral artery disease, REACH Registry, Risk factor control",

author = "Cacoub, {Patrice P.} and Abola, {Maria Teresa B} and Iris Baumgartner and Bhatt, {Deepak L.} and Creager, {Mark A.} and Liau, {Chiau Suong} and Shinya Goto and Joachim R{\"o}ther and Steg, {P. Gabriel} and Hirsch, {Alan T.}",

note = "Funding Information: Funding: The REACH Registry is sponsored by sanofi-aventis (Paris, France), Bristol-Myers Squibb (Princetown, New Jersey, USA), and the Waksman Foundation (Tokyo, Japan). The sponsors provide logistical support. All the publication activity is controlled by the REACH Registry Global Publication Committee (Ph. Gabriel Steg, Deepak L. Bhatt, Mark Alberts, Ralph D{\textquoteright}Agostino, Kim Eagle, Shinya Goto, Alan T. Hirsch, Chiau-Suong Liau, Jean-Louis Mas, E. Magnus Ohman, Joachim R{\"o}ther, Sidney C. Smith, Peter W.F. Wilson). All manuscripts in the REACH Registry are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publication committee before submission. The funding sponsors have the opportunity to review manuscript submissions but do not have authority to change any aspect of a manuscript. Funding Information: Prof. Creager is the recipient of research grants from sanofi-aventis and Merck and is on the speaker's bureau for the Bristol-Myers Squibb – sanofi-aventis Partnership. He is a consultant for Genzyme, Merck, Sigma Tau, and Vascutec. Funding Information: Dr. Hirsch has received research grants from Bristol-Myers Squibb and sanofi-aventis and honoraria from sanofi-aventis. Funding Information: Prof. Steg has received honoraria for advisory board attendance and consulting fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharpe and Dohme, Nycomed, sanofi-aventis, Servier, Takeda, The Medicines Company; speakers bureau from Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Nycomed, sanofi-aventis, Servier, ZLB Behring and Research Grant from sanofi-aventis within the last 3 years. ",

year = "2009",

month = jun,

doi = "10.1016/j.atherosclerosis.2008.10.023",

language = "English (US)",

volume = "204",

pages = "e86--e92",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry

AU - Cacoub, Patrice P.

AU - Abola, Maria Teresa B

AU - Baumgartner, Iris

AU - Bhatt, Deepak L.

AU - Creager, Mark A.

AU - Liau, Chiau Suong

AU - Goto, Shinya

AU - Röther, Joachim

AU - Steg, P. Gabriel

AU - Hirsch, Alan T.

N1 - Funding Information: Funding: The REACH Registry is sponsored by sanofi-aventis (Paris, France), Bristol-Myers Squibb (Princetown, New Jersey, USA), and the Waksman Foundation (Tokyo, Japan). The sponsors provide logistical support. All the publication activity is controlled by the REACH Registry Global Publication Committee (Ph. Gabriel Steg, Deepak L. Bhatt, Mark Alberts, Ralph D’Agostino, Kim Eagle, Shinya Goto, Alan T. Hirsch, Chiau-Suong Liau, Jean-Louis Mas, E. Magnus Ohman, Joachim Röther, Sidney C. Smith, Peter W.F. Wilson). All manuscripts in the REACH Registry are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publication committee before submission. The funding sponsors have the opportunity to review manuscript submissions but do not have authority to change any aspect of a manuscript. Funding Information: Prof. Creager is the recipient of research grants from sanofi-aventis and Merck and is on the speaker's bureau for the Bristol-Myers Squibb – sanofi-aventis Partnership. He is a consultant for Genzyme, Merck, Sigma Tau, and Vascutec. Funding Information: Dr. Hirsch has received research grants from Bristol-Myers Squibb and sanofi-aventis and honoraria from sanofi-aventis. Funding Information: Prof. Steg has received honoraria for advisory board attendance and consulting fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharpe and Dohme, Nycomed, sanofi-aventis, Servier, Takeda, The Medicines Company; speakers bureau from Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Nycomed, sanofi-aventis, Servier, ZLB Behring and Research Grant from sanofi-aventis within the last 3 years.

PY - 2009/6

Y1 - 2009/6

N2 - Objectives: To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates. Methods: The REACH Registry recruited >68000 outpatients aged ≥45 years with established atherothrombotic disease or ≥3 RFs for atherothrombosis. The predictors of RF control that were evaluated included: (1) patient demographics, (2) mode of PAD diagnosis, and (3) concomitant CAD and/or CVD. Results: RF control was less frequent in patients with PAD (n = 8322), compared with those with CAD or CVD (but no PAD, n = 47492) [blood pressure; glycemia; total cholesterol; smoking cessation (each P < 0.001)]. Factors independently associated with optimal RF control in patients with PAD were male gender (OR = 1.9); residence in North America (OR = 3.5), Japan (OR = 2.5) or Latin America (OR = 1.5); previous coronary revascularization (OR = 1.3); and statin use (OR = 1.4); whereas prior leg amputation was a negative predictor (OR = 0.7) (P < 0.001). Optimal RF control was associated with fewer 1-year CV ischemic symptoms or events. Conclusions: Patients with PAD do not achieve RF control as frequently as individuals with CAD or CVD. Improved RF control is associated with a positive impact on 1-year CV event rates.

AB - Objectives: To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates. Methods: The REACH Registry recruited >68000 outpatients aged ≥45 years with established atherothrombotic disease or ≥3 RFs for atherothrombosis. The predictors of RF control that were evaluated included: (1) patient demographics, (2) mode of PAD diagnosis, and (3) concomitant CAD and/or CVD. Results: RF control was less frequent in patients with PAD (n = 8322), compared with those with CAD or CVD (but no PAD, n = 47492) [blood pressure; glycemia; total cholesterol; smoking cessation (each P < 0.001)]. Factors independently associated with optimal RF control in patients with PAD were male gender (OR = 1.9); residence in North America (OR = 3.5), Japan (OR = 2.5) or Latin America (OR = 1.5); previous coronary revascularization (OR = 1.3); and statin use (OR = 1.4); whereas prior leg amputation was a negative predictor (OR = 0.7) (P < 0.001). Optimal RF control was associated with fewer 1-year CV ischemic symptoms or events. Conclusions: Patients with PAD do not achieve RF control as frequently as individuals with CAD or CVD. Improved RF control is associated with a positive impact on 1-year CV event rates.

KW - Cardiovascular events

KW - Cohort study

KW - Peripheral artery disease

KW - REACH Registry

KW - Risk factor control

UR - http://www.scopus.com/inward/record.url?scp=67349127553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349127553&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.10.023

DO - 10.1016/j.atherosclerosis.2008.10.023

M3 - Article

C2 - 19054514

AN - SCOPUS:67349127553

SN - 0021-9150

VL - 204

SP - e86-e92

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -

Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this